PDO Screen – Patient-derived Organoids meet Cancer Modeling
Discover how patient-derived organoids can revolutionize oncology research by enabling accurate modeling of tumor biology and predicting patient response to treatment. (more…)
March 21, 2023
Discover how patient-derived organoids can revolutionize oncology research by enabling accurate modeling of tumor biology and predicting patient response to treatment. (more…)
January 16, 2023
Explore what the new legislative bill means for the future of organoid technology in drug development The use of animals to test...
November 1, 2022
Learn how to select the right model for your immunotherapy development Over the past decade, immunotherapy has revolutionized oncology. From ipilimumab improving...
July 7, 2022
Explore HUB’s license offerings and how they apply to your organoid research projects HUB’s proprietary technology enables the production of mini-organs in...
May 17, 2022
Learn why you should invest in patient-derived HUB Organoids® for your drug screening program Drug discovery is like horse betting, except it...
October 14, 2021
In this last episode of our "Ask the experts" series we explore the difference between HUB Organoids™ and iPSCs-derived organoids and discuss...
September 30, 2021
After discussing HUB Organoids™ applications to viral and oncology studies, Drs Rob Vries, CEO and Sylvia Boj CSO from HUB review together...
September 9, 2021
In the first post from our "Ask the experts" series we have answered the most commonly asked questions around the applications of...
August 25, 2021
HUB and STEMCELL Technologies experts gathered virtually for a mini-symposium to discuss the development and characterization of organoids, how they are applied...
